2025-09-11T14:27:40-05:00 2024-12-31 131655065 LUTZ AND CARR CPAS LLP 551 FIFTH AVENUE SUITE 400 NEW YORK NY 10176 990 2024-01-01 582492929 LUPUS RESEARCH ALLIANCE INC LUPU 6468846000 270 MADISON AVENUE SUITE 300 NEW YORK NY 10016 DEBRA ROSE CHIEF FINANCIAL OFFICER 2122182840 2025-09-11 1 0 JENNIFER COATES P02247728 2126972299 2024 2025-03-06 01:10:19Z ALBERT T ROY 270 MADISON AVENUE SUITE 300 NEW YORK NY 10016 31453401 0 X LUPUSRESEARCH.ORG X 1999 NY FREEING THE WORLD OF LUPUS. 25 25 72 500 0 0 41038661 11172604 1197560 1874491 8063403 4937822 561873 570065 50861497 18554982 16607966 15491102 0 0 9057340 11287230 72500 75000 4204298 9667445 11322100 35405251 38175432 15456246 -19620450 111947130 93254416 36633486 37541841 75313644 55712575 X PUTTING PEOPLE WITH LUPUS AT THE CENTER OF ALL WE DO, THE LUPUS RESEARCH ALLIANCE DRIVES THE DISCOVERY & DEVELOPMENT OF NEXT GENERATION LUPUS DIAGNOSTICS AND CURATIVE TREATMENTS THROUGH INNOVATIVE RESEARCH & COLLABORATIONS. 0 0 14619194 12856659 THE LUPUS RESEARCH ALLIANCE (LRA), THE LARGEST NON-GOVERNMENTAL, PRIVATE FUNDER OF LUPUS RESEARCH WORLDWIDE: FUNDS INNOVATIVE RESEARCH THAT SPANS THE SPECTRUM FROM FOUNDATIONAL TO CLINICAL RESEARCH. FOSTERS DIVERSE SCIENTIFIC TALENT, STIMULATES COLLABORATIONS, AND DRIVES DISCOVERIES TO TRANSFORM TREATMENT WHILE ADVANCING TOWARD A CURE. HAS INVESTED NEARLY $272 MILLION IN LUPUS RESEARCH INCLUDING 620+ RESEARCH GRANTS LRA-FUNDED RESEARCH PAVED THE WAY FOR THE ONLY TWO BIOLOGIC DRUGS CURRENTLY APPROVED FOR LUPUS, AND THE LRA IS INVOLVED IN NUMEROUS ONGOING PHASE 3 TRIALS. FURTHER, LRA RESEARCH INVESTMENTS HAVE CONTRIBUTED TO THE IDENTIFICATION OR FURTHER VALIDATION OF TWO DOZEN DISEASE PATHWAYS IN LUPUS AND HAVE ENABLED THE DISCOVERY, PROOF OF CONCEPT, OR DEVELOPMENT OF MORE THAN A DOZEN DIFFERENT NEW THERAPIES FOR LUPUS. SINCE THE FORMATION OF THE LUPUS CLINICAL INVESTIGATORS NETWORK (LUCIN), LRA HAS DEDICATED $34 MILLION TO BOLSTER LUPUS CLINICAL RESEARCH INFRASTRUCTURE AND QUALITY.THE ORGANIZATION'S RESEARCH COMMITTEE OF THE BOARD OF DIRECTORS AND SCIENTIFIC ADVISORY BOARD INCLUDES TOP SCIENTIFIC EXPERTS, AND KEY LAY MEMBERS OF THE LRA'S BOARD OF DIRECTORS, WHO WORK WITH STAFF TO STRATEGICALLY GUIDE AND DRIVE THE RESEARCH FUNDING AGENDA.IN 2024 ALONE, OVER $12 MILLION WAS AWARDED IN GRANTS FOR 38 HIGHLY INNOVATIVE PROJECTS WITH THE POTENTIAL TO IMPROVE TREATMENT AS WELL AS UNDERSTAND THE CAUSES OF LUPUS AND THUS LEAD TO A CURE. BELOW IS A SUMMARY OF RESEARCH GRANTS AND PROGRAMS FUNDED BY THE LRA IN 2024: 1) 11 LUPUS INNOVATION AWARD GRANTS WERE AWARDED TOTALING ALMOST $4 MILLION OVER TWO YEARS, THIS PROGRAM SUPPORTS PIONEERING, HIGH-RISK, HIGH-REWARD PROJECTS ADDRESSING MAJOR CHALLENGES IN LUPUS RESEARCH. EARLY-STAGE INVESTIGATORS ARE GIVEN SPECIAL CONSIDERATION DURING THE REVIEW PROCESS AND ARE ELIGIBLE FOR A THIRD YEAR OF FUNDING; 2) 6 ADMINISTRATIVE LUPUS RESEARCH SUPPLEMENT GRANTS WERE AWARDED TOTALING $90,000. THIS PROGRAM SUPPORTS PROMISING TRAINEES WHO ARE WORKING WITH LRA-FUNDED RESEARCHERS OR INVESTIGATORS FOCUSED ON AUTOIMMUNITY SUPPORTED BY THE NATIONAL INSTITUTES OF HEALTH (NIH), DEPARTMENT OF DEFENSE (DOD), OR EQUIVALENT GRANTS IN GOOD STANDING. 3) 3 GRANTS TOTALING APPROXIMATELY $1.8 MILLION WERE AWARDED TO RESEARCHERS IN THE CAREER DEVELOPMENT AWARD PROGRAM THAT AIMS TO SUPPORT EARLY CAREER INVESTIGATORS FOR THE PERIOD BETWEEN THE COMPLETION OF POST-DOCTORATE FELLOWSHIP TRAINING AND ESTABLISHMENT AS AN INDEPENDENT INVESTIGATOR. THE PROGRAM PROVIDES UP TO $600,000 OVER FOUR YEARS. 4) 2 POSTDOCTORAL GRANTS FELLOWSHIP GRANTS AWARDED, THIS GRANT IS DESIGNED TO FUND PROMISING RESEARCH FELLOWS AND PROVIDES THEM WITH UP TO $170,000 OVER TWO YEARS TO SUPPORT THE GENERATION OF DATA, UNIQUE RESEARCH IDEAS AND PROGRESS TO TRANSITION TO AN INDEPENDENT RESEARCH ROLES FOCUSED ON LUPUS RESEARCH. 5) 5 TRANSLATIONAL BRIDGE AWARDS FUNDED TOTALING APPROXIMATELY $2.2 MILLION. THIS PROGRAM PROVIDES UP TO $450,000 OVER TWO YEARS, WITH A GOAL TO BRIDGE THE GAP BETWEEN POST-DISCOVERY AND PRE-COMMERCIAL DEVELOPMENT WITH AN AIM TO ACCELERATE THE PACE AT WHICH PROMISING LRA-FUNDED FOUNDATIONAL RESEARCH DISCOVERIES ARE TRANSLATED INTO CLINICAL EVALUATION AND TRANSITIONED TO A VIABLE PRODUCT THAT WILL IMPACT PATIENTS DIRECTLY. 6) 11 TARGETED RESEARCH PROGRAM ON ENGINEERED CELL THERAPIES FOR LUPUS GRANTS TOTALING OVER $4 MILLION. THIS PROGRAM ADVANCES THE DEVELOPMENT OF NEXT GENERATION ENGINEERED CELL THERAPIES WITH A CLEAR AND DIRECT RELEVANCE TO PEOPLE WITH LUPUS.7) THE LUPUS INSIGHT PRIZE WAS AWARDED $200,000. THIS AWARD RECOGNIZED TWO LEADING RESEARCHERS WHO HAVE MADE A MAJOR CONTRIBUTION RELEVANT TO LUPUS, AS PART THE LRA'S COMMITMENT TO COLLABORATION, THE LRA WORKS WITH A VARIETY OF PARTNERS ACROSS SECTORS AIMED AT ACCELERATING RESEARCH DISCOVERIES, LEVERAGING RESOURCES, AND EXPEDITING THE DRUG DEVELOPMENT PROCESS TO IMPROVE THE QUALITY OF LIFE OF PEOPLE LIVING WITH LUPUS BRINGING TOGETHER THE KEY PLAYERS IN THE FIGHT AGAINST LUPUS -- OUR GRANTEES, SCIENTIFIC ADVISORS, CLINICIANS, THE BIOPHARMACEUTICAL INDUSTRY, THE U.S. GOVERNMENT, AND PEOPLE LIVING WITH LUPUS. THE LRA'S ROBUST FUNDING MODEL SUPPORTS PROMISING RESEARCH EFFORTS WITH THE GOAL OF IMPROVING THE LIVES OF PEOPLE WITH LUPUS SOON. THROUGH COMPETITIVE PEER-REVIEW PROCESS PROJECTS BY THE LRA AIM TO TRANSLATE RESULTS FROM THE RESEARCH BENCH TO THE BEDSIDE AS QUICKLY AS POSSIBLE. BECAUSE THE LUPUS RESEARCH ALLIANCE'S BOARD OF DIRECTORS FUNDS THE ADMINISTRATIVE AND FUNDRAISING EXPENSES, 100% OF ALL OTHER CONTRIBUTIONS GOES TO SUPPORT THE LRA'S LUPUS RESEARCH PROGRAMS. 14814000 2634443 1874491 THE LUPUS RESEARCH ALLIANCE (LRA) HAS MADE SIGNIFICANT STRIDES IN ADVANCING ITS SCIENTIFIC MISSION THROUGH STRATEGIC PLANNING, PROGRAM EXPANSION AND OPERATIONAL IMPROVEMENTS.IN 2024, THE LRA SUCCESSFULLY DEVELOPED AND IMPLEMENTED THE FIRST-YEAR GOALS OF ITS 20242028 RESEARCH STRATEGY. IN ALIGNMENT WITH THE UPDATED RESEARCH STRATEGY, LRA LAUNCHED SEVERAL INNOVATIVE, PATIENT-CENTRIC RESEARCH INITIATIVES, INCLUDING THE TRANSLATIONAL BRIDGE AWARD, THE TARGETED RESEARCH PROGRAM ON ENGINEERED CELL THERAPIES, THE RENEWED CYCLE OF THE COMMON MECHANISMS IN AUTOIMMUNE DISEASES PROGRAM, AND THE MECHANISTIC CLINICAL STUDIES AWARD. ADDITIONALLY, THE ORGANIZATION BEGAN DEVELOPING A LUPUS BIOMARKERS STRATEGY AND INITIATED THE DEVELOPMENT OF A COMPREHENSIVE DATA STRATEGY, SCHEDULED FOR COMPLETION IN 2025.LRA'S CURRENT GRANT PROGRAMS, INCLUDING THE GLOBAL TEAM SCIENCE AWARD (GTSA), CAREER DEVELOPMENT AWARD, POST DOCTORAL AWARD, AND LUPUS INNOVATION AWARD --WERE EXPANDED AND OPTIMIZED THROUGH ACTIVE STAFF OVERSIGHT AND STRATEGIC COLLABORATIONS. THIS INCLUDED LAUNCHING A REQUEST FOR APPLICATIONS IN A COLLABORATIVE PROGRAM ACROSS THE GTSA AND CONTINUING THE ADMINISTRATIVE SUPPLEMENT TRAINING PROGRAM.TO RAISE THE VISIBILITY OF ITS RESEARCH PROGRAMS, LRA SUBMITTED MULTIPLE ABSTRACTS TO INTERNATIONAL SCIENTIFIC MEETINGS, SEVERAL WERE ACCEPTED AND WILL BE PRESENTED IN 2025. THE ORGANIZATION ALSO HOSTED A SUCCESSFUL AND ENGAGING ANNUAL INVESTIGATOR'S AND PROGRAM SPECIFIC MEETINGS: FORUM FOR DISCOVERY, ALLIANCE OF GTSA AND OTHER PROGRAM-SPECIFIC RESEARCH MEETINGS IN NOVEMBER OF 2024. OPERATIONAL IMPROVEMENTS INCLUDED THE SELECTION AND IMPLEMENTATION OF A NEW GRANT MANAGEMENT SYSTEM, THE RECRUITMENT AND ONBOARDING OF TWO STAFF SCIENTISTS AND A LUPUS ABC ADMINISTRATOR, AND THE STRENGTHENING OF THE RESEARCH TEAM THROUGH TARGETED TEAM-BUILDING AND PROFESSIONAL DEVELOPMENT EFFORTS. LUPUS ABC HAS BEEN SUCCESSFULLY ESTABLISHED AS A MODEL PUBLIC-PRIVATE PARTNERSHIP IN THE REGULATORY SPACE, DEMONSTRATING LEADERSHIP AND INNOVATION IN ADVANCING LUPUS RESEARCH AND EXPERIENCED SUBSTANTIAL GROWTH IN MEMBERSHIP DURING 2024. THE INITIATIVE SECURED ACTIVE PARTICIPATION FROM THE FDA'S CENTER FOR BIOLOGICS EVALUATION AND RESEARCH, REINFORCING ITS CREDIBILITY AND COLLABORATIVE STRENGTH. A MAJOR MILESTONE WAS THE FDA'S ACKNOWLEDGMENT OF CLASI 70 AS A PRIMARY EFFICACY ENDPOINT IN CUTANEOUS LUPUS CLINICAL TRIALS, MARKING A SIGNIFICANT ADVANCEMENT IN CLINICAL OUTCOME MEASUREMENT. ADDITIONALLY, LUPUS ABC CONVENED A DEDICATED PATIENT-REPORTED OUTCOMES (PRO) MEETING TO FURTHER INTEGRATE PATIENT PERSPECTIVES INTO RESEARCH AND REGULATORY STRATEGIES. LUPUS NEXUS COMPLETED ITS INFRASTRUCTURE BUILD AND OFFICIALLY LAUNCHED TO BOTH RESEARCH AND PATIENT COMMUNITIES. IT FINALIZED FOUNDATIONAL ANALYSIS PLANS, SELECTED KEY VENDORS, AND RECRUITED 200 PARTICIPANTS. ADDITIONALLY, 10 NEW CLINICAL SITES WERE ACTIVATED THROUGH LUCIN (SEE BELOW), AND A SUSTAINABLE FINANCIAL MODEL WITH A DEFINED MEMBERSHIP FEE STRUCTURE WAS ESTABLISHED. LUPUS THERAPEUTICS, LLC :THE LRA FOUNDED LUPUS THERAPEUTICS, LLC (LT) AS THE CLINICAL RESEARCH AFFILIATE OF THE LRA IN 2018. WITH THIS ADDITION, THE LRA IS THE ONLY ORGANIZATION LEADING LUPUS RESEARCH ACROSS THE CONTINUUM FROM ACCELERATING BASIC DISCOVERIES IN THE LAB THROUGH CLINICAL EVALUATION OF NEW THERAPIES. MANY OF THE BASIC RESEARCH BREAKTHROUGHS SUPPORTED BY THE LRA HAVE HELPED UNRAVEL THE COMPLEXITIES OF LUPUS AND ENABLED THE DEVELOPMENT OF POTENTIAL TREATMENTS AND DIAGNOSTICS NOW IN CLINICAL STUDIES. LT IS ACTIVELY SUPPORTING SEVERAL CLINICAL STUDIES FOR NEW THERAPIES THROUGH THE LUPUS CLINICAL INVESTIGATORS NETWORK (LUCIN). LT OVERSEES LUCIN, A NORTH AMERICA-BASED LUPUS CLINICAL TRIALS NETWORK OF 60+ PREMIER RESEARCH MEDICAL CENTERS. THE LRA PROVIDED OVER $2.6 MILLION IN GRANTS IN 2024 TO CONTINUE FUNDING TOP ACADEMIC CENTERS TO FOSTER ROBUST, HIGH QUALITY CLINICAL TRIAL CONDUCT WITH PARTICIPATION ACROSS NORTH AMERICA.LT ALSO OFFERS EXPERTISE COMBINED WITH THAT OF 250+ LUCIN PROVIDERS AND THE LRA TO SUPPORT ACADEMIC, NONPROFIT AND BIOTECH AND PHARMACEUTICAL ORGANIZATIONS TO PLAN, INITIATE AND MANAGE CLINICAL RESEARCH. THIS OCCURS THROUGH DIVERSE ADVISORY SERVICES AND DIRECT CLINICAL OPERATIONS SUPPORT. AN ANNUAL LUCIN COMMUNITY MEETING IS HELD TO BRING TOGETHER ALL OF THE PARTNERS IN CLINICAL RESEARCH TO HIGHLIGHT RECENT ADVANCEMENTS, BOLSTER UNDERSTANDING, ADDRESS CURRENT CHALLENGES IN CLINICAL RESEARCH AND ENCOURAGE COLLABORATION FOR SUCCESSFUL DEVELOPMENT OF NEW TREATMENT APPROACHES.IN ADDITION, LT HAS EXPANDED THE FIRST PEER-TO-PEER CLINICAL TRIALS EDUCATION PROGRAM, PATIENT ADVOCATES FOR LUPUS STUDIES OR PALS TO INCLUDE TRIAL BUDDY SUPPORT DURING PARTICIPATION IN CLINICAL TRIALS. PALS AIMS TO IMPROVE CLINICAL RESEARCH AWARENESS, KNOWLEDGE AND ENROLLMENT, WITH A SPECIFIC FOCUS ON MAKING SURE POPULATIONS AT GREATEST RISK FOR LUPUS ARE WELL REPRESENTED IN STUDIES. LT ALSO SUPPORTS OTHER PATIENT ENGAGEMENT ACTIVITIES SUCH AS PATIENT ADVISORY BOARDS, PATIENT VISITS AND PATIENT PROTOCOL REVIEW COMMITTEES TO ENSURE THAT INDIVIDUALS IMPACTED BY LUPUS HAVE A VOICE IN THE TREATMENT DEVELOPMENT PROCESS. FINALLY, LT EFFORTS SUPPORT VARIOUS EDUCATION OFFERINGS FOR PROVIDERS AND PATIENTS, AND COMMUNITY-BASED OUTREACH TO ENSURE REPRESENTATIVE PARTICIPATION OF THE ENTIRE LUPUS COMMUNITY IN CLINICAL RESEARCH. 571134 THE LUPUS RESEARCH ALLIANCE'S ADVOCACY EFFORTS FOCUS ON EDUCATING CONGRESS ABOUT LUPUS AND URGING CONGRESS AND THE ADMINISTRATION TO PROVIDE THE FUNDS AND SUPPORT NEEDED TO ADVANCE LUPUS RESEARCH THAT CAN LEAD TO BETTER TREATMENTS AND, ULTIMATELY, A CURE. EFFORTS ALSO INCLUDE WAYS TO ENSURE INCREASED DIVERSITY IN CLINICAL TRIALS AND REDUCING BARRIERS TO ENROLLMENT FOR ALL WHO WANT TO PARTICIPATE. THE TOP GOALS OF THE LUPUS RESEARCH ALLIANCE PUBLIC POLICY PROGRAM FOCUS MAINLY ON FUNDING FOR LUPUS RESEARCH THAT WILL LEAD TO BETTER TREATMENTS AND ELIMINATE RACIAL DISPARITIES IN HEALTHCARE. GOALS INCLUDE: INCREASING FEDERAL FUNDING FOR LUPUS RESEARCH AT THE NATIONAL INSTITUTES OF HEALTH (NIH), AND SPECIFICALLY THE NATIONAL INSTITUTE FOR ALLERGY & INFECTIONS DISEASE (NIAID) AND NATIONAL INSTITUTE FOR ARTHRITIS & MUSCULOSKELETAL DISORDERS (NIAMS). ADDITIONALLY, LRA ADVOCATES FOR LUPUS RESEARCH THROUGH THE DEPARTMENT OF DEFENSE (DOD); SUPPORTING THE LRA'S PARTNERSHIP WITH THE FDA, THE LUPUS ACCELERATING BREAKTHROUGHS CONSORTIUM (LUPUS ABC); AND ENSURING THE PATIENT VOICE IS INCORPORATED IN THE DRUG DEVELOPMENT PROCESS. VOLUNTEERS ACROSS THE COUNTRY HELP AMPLIFY THESE OUTREACH EFFORTS.THROUGH THE LUPUS RESEARCH ALLIANCE ONGOING PUBLIC POLICY PROGRAM EFFORTS, SIGNIFICANT FUNDING FOR LUPUS RESEARCH HAS BEEN OBTAINED UNDER THE DEPARTMENT OF DEFENSE (DOD) CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS (CDMRP) OPERATED BY THE ARMY MEDICAL RESEARCH AND MATERIEL COMMAND. GIVEN THE HIGH DEMAND FOR NEW RESEARCH ALONGSIDE THE RISING NUMBERS OF WOMEN TREATED AT MILITARY HEALTH FACILITIES AS WELL AS THE LINK BETWEEN POST-TRAUMATIC STRESS DISORDER (PTSD) AND THE DEVELOPMENT OF AN AUTOIMMUNEDISEASE, THE LUPUS RESEARCH ALLIANCE HAS WORKED TO CONVINCE CONGRESS TO INCREASE ITS INVESTMENT AND PROVIDE $15 MILLION FOR THE LUPUS RESEARCH PROGRAM IN THE CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS OPERATED UNDER THE DEFENSE HEALTH PROGRAM IN THE DEFENSE APPROPRIATIONS BILL. THIS ADDITIONAL INVESTMENT IS CRITICAL FOR DISCOVERIES THAT CAN MAKE A DIFFERENCE IN PATIENTS' ABILITY TO BE THE BEST VERSION OF THEMSELVES. THE LRA LED THE PUSH FOR THE CREATION OF THE LUPUS RESEARCH PROGRAM, WHICH WAS FIRST FUNDED WITH $5 MILLION IN 2017 AND INCREASED TO $10 MILLION PER YEAR IN 2020. LRA LEADERSHIP, OUR ADVOCATES, AND ALLIED MEMBERS OF CONGRESS ARE WORKING TO ADVANCE RESEARCH PRIORITIES LIKE THIS THAT ARE CRITICAL TO THE LUPUS RESEARCH ALLIANCE AND ALL PEOPLE IMPACTED BY LUPUS.IN 2024, AS THE THREAT OF CUTS TO HEALTH RESEARCH FUNDING BECAME MORE PRONOUNCED, THE LUPUS RESEARCH ALLIANCE INTENSIFIED ITS ADVOCACY TO PROTECT AND EXPAND SUPPORT FOR LUPUS RESEARCH. LRA'S PRIMARY ADVOCACY PUSH CENTERED ON ENCOURAGING CONSTITUENTS TO ENGAGE WITH THEIR HOUSE LEGISLATORS DURING THE AUGUST CONGRESSIONAL RECESS. TO SUPPORT THIS EFFORT, LRA LAUNCHED A WEBPAGE WITH RESOURCES TO HELP ADVOCATES LOCATE THEIR LEGISLATORS AND IDENTIFY LOCAL TOWN HALLS AND EVENTS. ADDITIONALLY, STAFF HELD A VIRTUAL OFFICE HOUR SESSION TO ANSWER QUESTIONS AND HELP ADVOCATES PREPARE TO SHARE THEIR STORIES AND EMPHASIZE THE IMPORTANCE OF RESEARCH FUNDING.ONGOING ADVOCACY FOCUSES ON ENSURING LEGISLATION THAT SECURES THE FEDERAL FUNDING SUPPORT NECESSARY TO AFFORD INVESTIGATORS THE RESOURCES TO FOLLOW THROUGH WITH RESEARCH DISCOVERIES THAT WILL IMPROVE THE UNDERSTANDING OF AND TREATMENT FOR LUPUS. EACH SPRING, LUPUS RESEARCH ADVOCATES MEET WITH MEMBERS OF CONGRESS AND THEIR STAFF TO DESCRIBE THEIR PERSONAL LUPUS JOURNEY AND HOW THE DISEASE HAS AFFECTED THEIR LIFE, AND TO REQUEST SPECIFIC POLICIES THAT WILL MOVE LUPUS RESEARCH FORWARD. THE GOAL IS TO INCREASE AWARENESS OF LUPUS AND THE IMPACT IT HAS ON PEOPLE'S DAILY LIVES TO MEMBERS OF CONGRESS AND TO REQUEST THEIR SUPPORT FOR INCREASED FUNDING FOR LUPUS RESEARCH FROM FEDERAL PROGRAMS SUCH AS THE NIH AND CDMRP. 30004328 1 1 0 1 0 0 0 0 0 1 1 0 0 0 1 0 0 1 0 0 1 1 1 1 1 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 1 120 0 1 72 1 0 0 0 0 0 1 1 0 0 0 0 0 0 X 25 25 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AL AK AZ AR CA CO CT FL GA HI IL KS KY ME MD MA MI MN MS MO NH NJ NM NY NC ND OH OK OR PA RI SC TN VA WA WV WI X X X DEBRA ROSE 6468846000 270 MADISON AVE SUITE 300 NEW YORK NY 10016 IRA AKSELRAD CHAIR 1.00 X X 0 0 0 JOSEPH MAURIELLO TREASURER 1.00 X X 0 0 0 ANNA FISCH SECRETARY 1.00 X X 0 0 0 JAMES ANDREW DIRECTOR 1.00 X 0 0 0 BISHOP RUDY V CARLTON DIRECTOR 1.00 X 0 0 0 WILLIE COLON DIRECTOR 1.00 X 0 0 0 ANDREW C CHAN DIRECTOR 1.00 X 0 0 0 JENNIFER DAKIN DIRECTOR 1.00 X 0 0 0 JENNIE DESCHERER DIRECTOR 1.00 X 0 0 0 KATEY DRISCOLL DIRECTOR 1.00 X 0 0 0 MOTI FERDER DIRECTOR 1.00 X 0 0 0 XAVIER GROSS DIRECTOR 1.00 X 0 0 0 JOE GERMANOTTA DIRECTOR 1.00 X 0 0 0 DAVID KIES DIRECTOR 1.00 X 0 0 0 GARY KORETSKY DIRECTOR 1.00 X 0 0 0 DANIEL LAVECCHIA DIRECTOR 1.00 X 0 0 0 VERONICA VARGAS LUPO DIRECTOR 1.00 X 0 0 0 NADEEM MEGHJI DIRECTOR 1.00 X 0 0 0 WILLIAM J MULVIHILL DIRECTOR 1.00 X 0 0 0 NIDHI PATEL DIRECTOR 1.00 X 0 0 0 ROBERT SEDER MD DIRECTOR 1.00 X 0 0 0 DANIEL J WALLACE DIRECTOR 1.00 X 0 0 0 JULIUS WILLIAMS DIRECTOR 1.00 X 0 0 0 WILLIAM WOLFE DIRECTOR 1.00 X 0 0 0 SPENCER ZWICK DIRECTOR 1.00 X 0 0 0 ALBERT ROY CEO AND PRESIDENT 40.00 X 427429 0 92685 STACIE BELL PHD CHIEF CLINICAL RESEARCH OFFICER 40.00 X 301419 0 50676 DEBRA ROSE CHIEF FINANCAL OFFICER 40.00 X 259368 0 84594 TEODORA STAEVA CHIEF SCIENTIFIC OFFICER 40.00 X 325453 0 81570 ANDREA O'NEILL VP, DEVELOPMENT 40.00 X 248348 0 44585 PENELOPE MITCHELL VP OF COMMUNICATIONS 40.00 X 210708 0 47301 LUKE EASLEY VP OF HR & ADMINISTRATION 40.00 X 233917 0 42715 DEVON KELLY LUPUS NEXUS DIRECTOR 40.00 X 226537 0 46357 DOREY NEILINGER SENIOR DIRECTOR OF PHILANTHROPY 40.00 X 189043 0 47611 HOANG NGUYEN DIRECTOR OF SCIENTIFIC PARTNERSHIP 40.00 X 167678 0 39601 JONATHAN MARKS DIRECTOR OF CORPORATE DEVELOPMENT 40.00 X 147444 0 52686 KENNETH M FABER FORMER CEO & PRESIDENT 40.00 X 375000 0 0 JENNIFER MERIWETHER CLIN OPS DIRECTOR, LT 40.00 X 199140 0 39763 3311484 0 670144 13 1 1 0 EG&A CIRP DBA MCS HEALTHCARE PR 110 ALLEN ROAD SUITE 300 BASKING RIDGE NJ 07921 PUBLIC RELATIONS CONSULTANT 337767 SCHANER & LUBITZ PLLC 4550 MONTGOMERY AVE SUITE 1100 N BETHESDA MD 20814 LIFE SCIENCES ATTORNEY 236624 KDH RESEARCH AND COMMUNICATION INC 145 15TH STREET NE SUITE 831 ATLANTA GA 30309 CHANGE CONSULTANT 221900 DECISION INFORMATION RESOURCES INC 3900 ESSEX LANE SUITE 900 HOUSTON TX 77027 CHANGE CONSULTANT 200000 LAUTMAN MASKA NEIL AND CO 1703 RHODE ISLAND AVE NW STE 301 WASHINGTON DC 20036 DIRECT RESPONSE CONSULTANT 161000 10 3788150 7384454 166624 11172604 LUCIN CONSULTING REVENUE 900099 1874491 1874491 1874491 1867297 1867297 15276526 12206001 3070525 3070525 3070525 692418 3788150 692418 0 SUBLET INCOME 900099 570065 570065 570065 18554982 1874491 0 5507887 12646443 12646443 2844659 2844659 2482569 1462319 485262 534988 6266791 3994959 1016399 1255433 431227 278018 65163 88046 1467433 932484 234951 299998 639210 400273 108162 130775 251042 197306 40970 12766 78240 78240 180399 180399 75000 75000 173130 173130 2655114 1432005 440411 782698 175477 115012 41102 19363 2267826 1933319 188519 145988 848409 204189 576376 67844 692907 436974 163243 92690 1535283 1373398 136533 25352 115082 71561 19987 23534 87160 57290 13636 16234 CLINICAL STUDIES 1242977 1242977 PRINTING & PUBLICATIONS 387425 69209 58664 259552 POSTAGE, SHIPPING & DEL 188690 12272 10744 165674 PROFESSIONAL DEVELOPMEN 120458 34649 84833 976 322481 84613 30481 207387 38175432 30004328 3966806 4204298 4319024 3033725 255096 259307 21589284 13309587 336389 281210 826852 635827 1074232 892185 262745 182047 80913435 73055389 855454 598131 2588851 1899193 111947130 93254416 1362369 2313310 31537305 32647877 3733812 2580654 36633486 37541841 X 47936256 34833646 27377388 20878929 75313644 55712575 111947130 93254416 X -19620450 -288960 308341 X 0 1 X 1 0 X 41539746 18941837 18375553 41038661 11172604 131068401 41539746 18941837 18375553 41038661 11172604 131068401 67824432 63243969 1614390 2025770 2655902 1929526 1867297 10092885 141161286 6632924 0.44800 0.46330 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 571134 571134 37604298 38175432 1000000 250000 0 0 1000000 1000000 1000000 1000000 4000000 6000000 647293 622162 761506 571134 2602095 250000 250000 250000 250000 1000000 1500000 51925078 2690242 4009849 50605471 53986019 1956112 4017053 51925078 61314537 -3669040 3659722 53986019 56586437 7839333 3111233 61314537 51813456 6226708 1453727 56586437 1.00000 0 0 1074232 892185 182047 182047 OPERATING LEASE LIABILITIES 2580654 2580654 18401233 -288960 308341 19381 18381852 173130 173130 18554982 38002302 0 38002302 173130 173130 38175432 PART V, LINE 4: BOARD DESIGNATED (QUASI) ENDOWMENT FUND INCOME TO BE USED FOR SUPPORTING OPERATIONS AND THE RESEARCH PROGRAM. PRINCIPAL TO REMAIN INTACT UNLESS HIGH PRIORITY LUPUS RESEARCH PROJECTS NEED TO BE FUNDED THAT COULD NOT BE FUNDED OTHERWISE. 1 NORTH AMERICA - CANADA AND MEXICO, BUT NOT THE UNITED STATES 0 0 GRANTS TO RECIPIENTS 684695 EAST ASIA AND THE PACIFIC 0 0 GRANTS TO RECIPIENTS 851280 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM 0 0 GRANTS TO RECIPIENTS 1308684 0 0 0 0 0 0 2844659 0 2844659 NORTH AMERICA LUPUS RESEARCH 293046 ACH 0 NORTH AMERICA LUPUS RESEARCH 16384 ACH 0 NORTH AMERICA LUPUS RESEARCH 29000 WIRE 0 NORTH AMERICA LUPUS RESEARCH 19875 CHECK 0 NORTH AMERICA LUPUS RESEARCH 37538 CHECK 0 NORTH AMERICA LUPUS RESEARCH 34352 CHECK 0 NORTH AMERICA LUPUS RESEARCH 18000 CHECK 0 NORTH AMERICA LUPUS RESEARCH 23063 ACH 0 NORTH AMERICA LUPUS RESEARCH 30653 CHECK 0 NORTH AMERICA LUPUS RESEARCH 182784 CHECK 0 EAST ASIA AND THE PACIFIC LUPUS RESEARCH 751880 WIRE 0 EUROPE (INCLUDING ICELAND AND GREENLAND) LUPUS RESEARCH 698996 WIRE 0 EUROPE (INCLUDING ICELAND AND GREENLAND) LUPUS RESEARCH 10000 WIRE 0 EUROPE (INCLUDING ICELAND AND GREENLAND) LUPUS RESEARCH 300000 WIRE 0 EUROPE (INCLUDING ICELAND AND GREENLAND) LUPUS RESEARCH 299688 WIRE 0 11 4 DATA STRATEGY EAST ASIA AND THE PACIFIC 1 99400 WIRE BOOK 0 0 0 0 0 0 PART I, LINE 2: PRE AWARD AND APPLICATION PHASE: BEFORE A GRANT IS AWARDED, DURING THE APPLICATION PHASE, THE SPONSORING INSTITUTION (SI) MUST AGREE THAT THEY WILL AGREE TO THE TERMS AND CONDITIONS OUTLINED IN THE LUPUS RESEARCH ALLIANCE (LRA)'S GRANT-SPECIFIC POLICY STATEMENT FOR RESEARCH GRANTS THAT INCLUDE: A. CONFIRMATION BY THE PRINCIPAL INVESTIGATOR (PI) AND THE SI THAT FUNDS WILL ONLY BE USED AS DESCRIBED IN THE APPLICATION SUBMITTED AND APPROVED FOR FUNDING. B. AGREE THAT PI AND SI ARE BOTH RESPONSIBLE FOR INSURING THAT ALL RESEARCH ACTIVITIES ARE CONDUCTED IN A SAFE, RESPONSIBLE AND ETHICAL MANNER. THEY MUST KEEP UPDATED APPROVAL FROM THE SI'S INSTITUTIONAL REVIEW BOARD AND ANIMAL CARE AND USE COMMITTEE THROUGHOUT THE PROJECT PERIOD. C. AGREE TO GET APPROVAL FROM THE LRA IF THERE NEEDS TO BE A SIGNIFICANT CHANGE TO THE BUDGET AS SUBMITTED. D. AGREE TO GET APPROVAL FROM THE LRA IF ADDITIONAL TIME IS NEEDED TO COMPLETE THE PROJECT WORK. E. AGREE TO SUBMIT ALL DELIVERABLES AND REPORTS AS SCHEDULED: (A) ANNUAL PROGRESS REPORTS AND (B) ANNUAL FINANCIAL REPORTS ARE REQUIRED. F. TRAVEL FUNDS PROVIDED AS PART OF THE PROJECT ARE EXPECTED TO BE USED TO ATTEND THE LRA'S ANNUAL MEETING - FORUM FOR DISCOVERY. G. CONFIRMATION THAT THERE IS NO OTHER ACTIVE OR PENDING SUPPORT FOR THE SPECIFIC PROJECT THAT IS THE SUBJECT OF THE GRANT. POST AWARD PROJECT PHASE: THE PI AND A REPRESENTATIVE FROM THE SI MUST SUBMIT A SIGNED LETTER OF ACCEPTANCE CONFIRMING THE FOLLOWING: A. PI'S WILLINGNESS TO ADHERE TO THE TERMS OF THE BUDGET AS OUTLINED IN THE FUNDING LETTER. B. PI'S WILLINGNESS TO COMPLY WITH ALL OF THE CONDITIONS OUTLINED IN THE POLICY STATEMENT FOR RESEARCH GRANTS AND PATENT AND INTELLECTUAL PROPERTY POLICY. C. THAT THERE IS NO OVERLAPPING SOURCE OF SUPPORT FOR THE PROJECT THAT IS THE SUBJECT OF THE AWARD. OTHER FUNDING THAT MIGHT BE CONSTRUED AS OVERLAPPING, MUST BE EXPLAINED IN DETAIL. D. THAT THE PI WILL ACCEPT RESPONSIBILITY FOR THE SCIENTIFIC AND TECHNICAL CONDUCT OF THE PROJECT AND FOR THE PROVISION OF ALL PROGRESS REPORTS REQUIRED FROM INVESTIGATORS FUNDED BY A GRANT FROM THE LRA. E. PI'S WILLINGNESS TO COMPLETE A BRIEF SURVEY AND SUBMIT A COPY OF THEIR UP-TO-DATE CV TO THE LRA TWO AND FIVE YEARS AFTER THE GRANT END DATE. ALL SI'S RECEIVE A PAYMENT AND DELIVERABLES SCHEDULE AND THE PROJECT IS MONITORED BY: A. PERIODIC PROGRESS REPORTS B. PERIODIC FINAL REPORTS C. ANNUAL MILESTONES SCHEDULE D. ADHERENCE TO LRA TERMS AND CONDITIONS GRANT CHANGES: WHEN EXTENSIONS ARE AWARDED, ADDITIONAL PROGRESS REPORTS AND FINANCIAL REPORTS ARE REQUIRED. AT THE END OF THE GRANT, FINAL PROGRESS AND FINANCIAL REPORTS ARE REQUIRED; UNSPENT AMOUNTS OVER $500 ARE TO BE RETURNED TO THE LRA. A. THE LRA MUST BE LISTED AS A FUNDER IN ANY PUBLISHED PAPERS AND ORAL OR POSTER PRESENTATIONS. B. THE SI MUST SUBMIT A COPY OF THE IRS DETERMINATION LETTER OR OTHER TAX GOVERNING INSTITUTION CONFIRMING THE TAX STATUS OF THE SI. X X X X X 1 DS CONSULTING GROUP 757 THIRD AVE 20TH FL NEW YORK NY 10017 SPECIAL EVENT CONSULTANT NY GALA 1 2719926 75000 2719926 2719926 75000 2719926 AL AK AZ AR CA CO CT DE FL GA HI ID IL IN IA KS KY LA ME MD MA MI MN MS MO MT NE NV NH NJ NM NY NC ND OH OK OR PA RI SC SD TN TX VT VA WA WV WI WY GALA CELEBRATION 3487331 2834005 653326 170135 244057 239134 WALK-A-THONS 993237 954145 39092 6613 4938 9575 17966 4480568 3788150 692418 6613 4938 179710 244057 257100 692418 0 SCHEDULE G, PART I, LINE 2B, COLUMN (V) DS CONSULTING PLANNED AND MANAGED LRA'S GALA EVENT. CONTRACT AMOUNT FOR THE PERIOD COVERING 1/1/24 - 12/31/24 WAS $75,500 PLUS REIMBURSABLE EXPENSES. 1 ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVE BRONX NY 10461 472209056 501(C)(3) 28743 0 LUPUS RESEARCH BOSTON CHILDREN'S HOSPTIAL 300 LONGWOOD AVENUE BOSTON MA 02115 042774441 501(C)(3) 919988 0 LUPUS RESEARCH BRIGHAM AND WOMEN'S HOSPITAL 77 AVENUE LOUIS PASTEUR BOSTON MA 02115 042312909 501(C)(3) 935996 0 LUPUS RESEARCH COLUMBIA UNIVERSITY MEDICAL CENTER 154 HAVEN AVE 2ND FL NEW YORK NY 10032 133598093 501(C)(3) 97762 0 LUPUS RESEARCH EMORY UNIVERSITY 1762 CLIFTON RD NE ATLANTA GA 30322 580566256 501(C)(3) 1287995 0 LUPUS RESEARCH FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH 350 COMMUNITY DRIVE MANHASSET NY 11030 112673595 501(C)(3) 368535 0 LUPUS RESEARCH FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH INC 9650 ROCKVILLE PIKE BETHESDA MD 20814 521986675 501(C)(3) 100000 0 LUPUS RESEARCH HOSPITAL FOR SPECIAL SURGERY 535 E 70TH STREET NEW YORK NY 10021 131624135 501(C)(3) 973154 0 LUPUS RESEARCH MASSACHUSETTS GENERAL HOSPITAL 55 FRUIT STREET BOSTON MA 02114 042697983 501(C)(3) 25729 0 LUPUS RESEARCH MAYO CLINIC 200 FIRST STREET SW ROCHESTER MN 55905 416011702 501(C)(3) 30453 0 LUPUS RESEARCH NEW YORK UNIVERSITY SCHOOL OF MEDICINE 550 FIRST AVENUE NEW YORK NY 10016 135562308 501(C)(3) 142715 0 LUPUS RESEARCH NORTHWELL HEALTH - DIVISION OF RHEUMATOLOGY 972 BRUSH HOLLOW RD 5TH FL WESTBURY NY 11590 112673595 501(C)(3) 40960 0 LUPUS RESEARCH NORTHWESTERN UNIVERSITY 633 CLARK STREET EVANSTON IL 60208 362167818 501(C)(3) 38847 0 LUPUS RESEARCH OKLAHOMA MEDICAL RESEARCH FOUNDATION 825 NE 13TH STREET OKLAHOMA CITY OK 73104 730580274 501(C)(3) 50087 0 LUPUS RESEARCH PENNSYLVANIA STATE UNIVERSITY ONE OLD MAIN UNIVERSITY PARK PA 16802 246000376 501(C)(3) 21678 0 LUPUS RESEARCH REGENTS OF THE UNIVERSITY OF CALIFORNIA IRVINE 5171 CALIFORNIA AVENUE STE 150 IRVINE CA 92697 952226406 501(C)(3) 30027 0 LUPUS RESEARCH RUSH UNIVERSITY MEDICAL CENTER 1653 WEST CONGRESS PARKWAY CHICAGO IL 60612 362174823 501(C)(3) 32392 0 LUPUS RESEARCH STANFORD UNIVERSITY 3145 PORTER DRIVE PALO ALTO CA 94304 941156365 501(C)(3) 319671 0 LUPUS RESEARCH STATE UNIVERSITY OF NY AT STONY BROOK ONE LINCOLN CENTER SYRACUSE NY 13202 141368361 501(C)(3) 23000 0 LUPUS RESEARCH THE METROHEALTH SYSTEM 2500 METROHEALTH DRIVE CLEVELAND OH 44109 346004382 SECTION 115 - OH STA 31314 0 LUPUS RESEARCH THE OHIO STATE UNIVERSITY 1960 KENNY ROAD COLUMBUS OH 43210 311702164 SECTION 115 - OH STA 127170 0 LUPUS RESEARCH REGENTS OF THE UNIVERSITY OF CALIFORNIA LOS ANGELES 10920 WILSHIRE BLVD STE 620 LOS ANGELES CA 90024 956006143 501(C)(3) 48441 0 LUPUS RESEARCH REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN DIEGO 9500 GILMAN DRIVE MC0934 LA JOLLA CA 92093 956006144 501(C)(3) 61175 0 LUPUS RESEARCH THE UNIVERSITY OF CHICAGO 5801 SOUTH ELLIS AVENUE STE 501 CHICAGO IL 60637 362177139 501(C)(3) 186154 0 LUPUS RESEARCH THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL 6000 FELDWOOD ROAD COLLEGE PARK GA 30349 566001393 501(C)(3) 182114 0 LUPUS RESEARCH TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 3451 WALNUT STREET PHILADELPHIA PA 19104 231352685 501(C)(3) 343842 0 LUPUS RESEARCH TULANE UNIVERSITY AKA THE TULANE EDUCATIONAL FUND 200 BROADWAY ST STE 120 NEW ORLEANS LA 70118 720423889 501(C)(3) 30000 0 LUPUS RESEARCH UNIVERSITY OF ALABAMA AT BIRMINGHAM 1530 3RD AVE S BIRMINGHAM AL 35294 636005396 501(C)(3) 92869 0 LUPUS RESEARCH UNIVERSITY OF CALIFORNIA SAN FRANCISCO 2200 UNIVERSITY HALL BERKELEY CA 94720 946036493 501(C)(3) 164938 0 LUPUS RESEARCH UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS 3100 MARINE ST 6TH FL BOULDER CO 80309 846000555 501(C)(3) 80498 0 LUPUS RESEARCH UNIVERSITY OF FLORIDA 207 TIGERT HALL GAINSEVILLE FL 32611 596002052 FL STATE GOVERNMENT 21000 0 LUPUS RESEARCH UNIVERSITY OF MARYLAND BALTIMORE 620 W LEXINGON STREET 4TH FL BALTIMORE MD 21201 521830242 SECTION 115 - MD STA 72612 0 LUPUS RESEARCH UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL 55 LAKE AVENUE NORTH WORCESTER MA 01655 043167325 MA STATE GOVERNMENT 185223 0 LUPUS RESEARCH UNIVERSITY OF MICHIGAN 503 THOMPSON STREET ANN ARBOR MI 48109 386006309 501(C)(3) 122959 0 LUPUS RESEARCH UNIVERSITY OF ROCHESTER 518 HYLAN BUILDING ROCHESTER NY 14627 160743209 501(C)(3) 134000 0 LUPUS RESEARCH UNIVERISTY OF SOUTHERN CALIFORNIA 1640 MARENGO STREET 7TH FL LOS ANGELES CA 90033 951642394 501(C)(3) 32000 0 LUPUS RESEARCH WASHINGTON UNIVERSITY SCHOOL OF MEDICINE MISSOURI ONE BROOKINGS DRIVE ST LOUIS MO 63130 430653611 501(C)(3) 30239 0 LUPUS RESEARCH UT SOUTHWESTERN MEDICAL CENTER 5323 HARRY HINES BLVD DALLAS TX 75390 746000203 TX STATE GOVERNMENT 47819 0 LUPUS RESEARCH VANDERBILT UNIVERSITY MEDICAL CENTER 1211 MEDICAL CENTER DRIVE NASHVILLE TN 37232 352528741 501(C)(3) 28241 0 LUPUS RESEARCH WAKE FOREST UNIVERSITY HEALTH SCIENCES MEDICAL CENTER BLVD WINSTONSALEM NC 27157 223849199 501(C)(3) 38000 0 LUPUS RESEARCH YALE UNIVERSITY BOX 208239 NEW HAVEN CT 06520 060646973 501(C)(3) 87232 0 LUPUS RESEARCH MEDICAL UNIVERSITY OF SOUTH CAROLINA 179 ASHLEY AVENUE CHARLESTON SC 29425 576028985 SECTION 115 - SC STA 798495 0 LUPUS RESEARCH RILITE FOUNDATION 530 EAST MAIN STREET CHARLOTTESVILLE VA 22902 472638830 501(C)(3) 30000 0 LUPUS RESEARCH UNIVERSITY OF HOUSTON 4800 CALHOUN ROAD HOUSTON TX 77004 746001399 501(C)(3) 600000 0 LUPUS RESEARCH SEATTLE CHILDREN'S HOSPITAL 818 STEWART ST SEATTLE WA 98145 910564748 501(C)(3) 769121 0 LUPUS RESEARCH BETH ISRAEL DEACONESS MEDICAL CENTER 330 BROOKLINE AVENUE BOSTON MA 02215 042103881 501(C)(3) 25525 0 LUPUS RESEARCH CEDARS-SINAI MEDICAL CENTER 8700 BEVERLY BLVD LOS ANGELES CA 90048 951644600 501(C)(3) 10000 0 LUPUS RESEARCH GEORGETOWN UNIVERSITY MEDICAL CENTER 3970 RERSERVOIR RD NW WASHINGTON DC 20057 530196603 501(C)(3) 10000 0 LUPUS RESEARCH LA JOLLA INSTITUTE FOR IMMUNOLOGY 9420 ATHENA CIR LA JOLLA CA 92037 330328688 501(C)(3) 449814 0 LUPUS RESEARCH MEMORIAL SLOAN-KETTERING CANCER CENTER 633 THIRD AVE 4TH FL NEW YORK NY 10017 131924236 501(C)(3) 300000 0 LUPUS RESEARCH UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE TUCSON 1501 N CAMPBELL AVE TUCSON AZ 85724 742652689 AZ STATE GOVERNMENT 37953 0 LUPUS RESEARCH UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE 3901 RAINBOW BLVD KANSAS CITY KS 66160 481108830 501(C)(3) 18000 0 LUPUS RESEARCH UNIVERSITY OF MIAMI 1320 S DIXIE HIGHWAY GABLES ONE TOWER 650 CORAL GABLES FL 33146 590624458 501(C)(3) 18000 0 LUPUS RESEARCH UNIVERSITY OF NEBRASKA MEDICAL CENTER 988145 NEBRASKA MEDICA CTR OMAHA NE 68198 911858433 501(C)(3) 49000 0 LUPUS RESEARCH UNIVERSITY OF NEVADA LAS VEGAS 4505 S MARYLAND PARKWAY LAS VEGAS NV 89154 886000024 NV STATE GOVERNMENT 24000 0 LUPUS RESEARCH UNIVERSITY OF PITTSBURGH 123 UNIVERSITY PLACE PITTSBURGH PA 15213 250965591 501(C)(3) 768000 0 LUPUS RESEARCH UNIVERSITY OF WASHINGTON 3917 UNIVERSITY WAY NE SEATTLE WA 98195 916001537 WA STATE GOVERNMENT 16112 0 LUPUS RESEARCH WALLACE RHEUMATIC STUDIES CENTER LLC 8737 BENVERLY BLVD STE 301 W HOLLYWOOD CA 90048 455434561 501(C)(3) 38373 0 LUPUS RESEARCH THE JACKSON LABORATORY 600 MAIN ST BAR HARBOR ME 04609 010211513 501(C)(3) 15000 0 LUPUS RESEARCH UNIVERSITY OF TENNESSEE HEALTH SCI CENTER 910 MADISON AVE STE 823 MEMPHIS TN 38163 626001636 SECTION 115 - TN STA 100000 0 LUPUS RESEARCH CASE WESTERN RESERVE UNIVERSITY 2103 CORNELL ROAD BLDG 2125 CLEVELAND OH 44106 341018992 501(C)(3) 298598 0 LUPUS RESEARCH FRED HUTCHINSON CANCER CENTER 1100 FAIRVIEW AVE N SEATTLE WA 98109 911935159 501(C)(3) 300000 0 LUPUS RESEARCH LELAND STANFORD JUNIOR UNIVERSITY 567 WILSON ROAD EAST LANSING MI 48824 386005984 501(C)(3) 10000 0 LUPUS RESEARCH 64 PART I, LINE 2: PRE AWARD AND APPLICATION PHASE: BEFORE A GRANT IS AWARDED, DURING THE APPLICATION PHASE, THE SPONSORING INSTITUTION (SI) MUST AGREE THAT THEY WILL AGREE TO THE TERMS AND CONDITIONS OUTLINED IN THE LUPUS RESEARCH ALLIANCE (LRA)'S GRANT-SPECIFIC POLICY STATEMENT FOR RESEARCH GRANTS THAT INCLUDE: A. CONFIRMATION BY THE PRINCIPAL INVESTIGATOR (PI) AND THE SI THAT FUNDS WILL ONLY BE USED AS DESCRIBED IN THE APPLICATION SUBMITTED AND APPROVED FOR FUNDING. B. AGREE THAT THE PI AND SI ARE BOTH RESPONSIBLE FOR INSURING THAT ALL RESEARCH ACTIVITIES ARE CONDUCTED IN A SAFE, RESPONSIBLE AND ETHICAL MANNER. THEY MUST KEEP UPDATED APPROVAL FROM THE SI'S INSTITUTIONAL REVIEW BOARD AND ANIMAL CARE AND USE COMMITTEE THROUGHOUT THE PROJECT PERIOD. C. AGREE TO GET APPROVAL FROM THE LRA IF THERE NEEDS TO BE A SIGNIFICANT CHANGE TO THE BUDGET AS SUBMITTED. D. AGREE TO GET APPROVAL FROM THE LRA IF ADDITIONAL TIME IS NEEDED TO COMPLETE THE PROJECT WORK. E. AGREE TO SUBMIT ALL DELIVERABLES AND REPORTS AS SCHEDULED: (A) ANNUAL PROGRESS REPORTS AND (B) ANNUAL FINANCIAL REPORTS ARE REQUIRED. F. TRAVEL FUNDS PROVIDED AS PART OF THE PROJECT ARE EXPECTED TO BE USED TO ATTEND THE LRA'S ANNUAL MEETING - FORUM FOR DISCOVERY. G. CONFIRMATION THAT THERE IS NO OTHER ACTIVE OR PENDING SUPPORT FOR THE SPECIFIC PROJECT THAT IS THE SUBJECT OF THE GRANT. POST AWARD PROJECT PHASE: THE PI AND A REPRESENTATIVE FROM THE SI MUST SUBMIT A SIGNED LETTER OF ACCEPTANCE CONFIRMING THE FOLLOWING: A. PI'S WILLINGNESS TO ADHERE TO THE TERMS OF THE BUDGET AS OUTLINED IN THE FUNDING LETTER. B. PI'S WILLINGNESS TO COMPLY WITH ALL OF THE CONDITIONS OUTLINED IN THE POLICY STATEMENT FOR RESEARCH GRANTS AND PATENT AND INTELLECTUAL PROPERTY POLICY. C. THAT THERE IS NO OVERLAPPING SOURCE OF SUPPORT FOR THE PROJEC TTHAT IS THE SUBJECT OF THE AWARD. OTHER FUNDING THAT MIGHT BE CONSTRUED AS OVERLAPPING, MUST BE EXPLAINED IN DETAIL. D. THAT THE PI WILL ACCEPT RESPONSIBILITY FOR THE SCIENTIFIC AND TECHNICAL CONDUCT OF THE PROJECT AND FOR THE PROVISION OF ALL PROGRESS REPORTS REQUIRED FROM INVESTIGATORS FUNDED BY A GRANT FROM THE LRA. E. PI'S WILLINGNESS TO COMPLETE A BRIEF SURVEY AND SUBMIT A COPY OF THEIR UP-TO-DATE CV TO THE LRA TWO AND FIVE YEARS AFTER THE GRANT END DATE. ALL SI'S RECEIVE A PAYMENT AND DELIVERABLES SCHEDULE AND THE PROJECT IS MONITORED BY: A. PERIODIC PROGRESS REPORTS B. PERIODIC FINAL REPORTS C. ANNUAL MILESTONE SCHEDULE D. ADHERENCE TO LRA TERMS AND CONDITIONS GRANT CHANGES: WHEN EXTENSIONS ARE AWARDED, ADDITIONAL PROGRESS REPORTS AND FINANCIAL REPORTS ARE REQUIRED. AT THE END OF THE GRANT, FINAL PROGRESS AND FINANCIAL REPORTS ARE REQUIRED; UNSPENT AMOUNTS OVER $500 ARE TO BE RETURNED TO THE LRA. THE LRA MUST BE LISTED AS A FUNDER IN ANY PUBLISHED PAPERS AND ORAL OR POSTER PRESENTATIONS. THE SI MUST SUBMIT A COPY OF THE IRS DETERMINATION LETTER OR OTHER TAX GOVERNING INSTITUTION CONFIRMING THE TAX STATUS OF THE SI. X X X X X X 0 0 0 0 0 0 0 0 0 ALBERT ROY CEO AND PRESIDENT 350397 0 75000 0 2032 0 34500 0 58185 0 520114 0 0 0 STACIE BELL PHD CHIEF CLINICAL RESEARCH OFFICER 258500 0 40000 0 2919 0 24000 0 26676 0 352095 0 0 0 DEBRA ROSE CHIEF FINANCAL OFFICER 231519 0 25000 0 2849 0 31301 0 53293 0 343962 0 0 0 TEODORA STAEVA CHIEF SCIENTIFIC OFFICER 273255 0 50000 0 2198 0 34481 0 47089 0 407023 0 0 0 ANDREA O'NEILL VP, DEVELOPMENT 245128 0 0 0 3220 0 26964 0 17621 0 292933 0 0 0 PENELOPE MITCHELL VP OF COMMUNICATIONS 185884 0 20000 0 4824 0 20720 0 26581 0 258009 0 0 0 LUKE EASLEY VP OF HR & ADMINISTRATION 197917 0 35000 0 1000 0 18553 0 24162 0 276632 0 0 0 DEVON KELLY LUPUS NEXUS DIRECTOR 214360 0 8694 0 3483 0 18084 0 28273 0 272894 0 0 0 DOREY NEILINGER SENIOR DIRECTOR OF PHILANTHROPY 179953 0 5491 0 3599 0 20530 0 27081 0 236654 0 0 0 HOANG NGUYEN DIRECTOR OF SCIENTIFIC PARTNERSHIP 157990 0 8000 0 1688 0 13439 0 26162 0 207279 0 0 0 JONATHAN MARKS DIRECTOR OF CORPORATE DEVELOPMENT 146437 0 0 0 1007 0 17233 0 35453 0 200130 0 0 0 KENNETH M FABER FORMER CEO & PRESIDENT 375000 0 0 0 0 0 0 0 0 0 375000 0 0 0 JENNIFER MERIWETHER CLIN OPS DIRECTOR, LT 197838 0 0 0 1302 0 15827 0 23936 0 238903 0 0 0 X 8 166624 AVG STOCK VALUE 0 1 1 PART I, LINE 32B: LRA HAS AN ACCOUNT WITH MORGAN STANLEY, WHICH LRA USES TO SELL THE CONTRIBUTIONS IT RECEIVES THOUGH STOCKS. FORM 990, PART VI, SECTION A, LINE 1A EXECUTIVE COMMITTEE IS COMPRISED OF THE BOARD CO-CHAIRS, PRESIDENT, BOARD SECRETARY AND ONE ADDITIONAL VOTING BOARD MEMBER. THE EXECUTIVE COMMITTEE APPROVES DETAILS OF PROGRAMS ALREADY APPROVED BY THE BOARD, STAFF COMPENSATION AND LARGE CONTRACT NEGOTIATIONS. FORM 990, PART VI, SECTION A, LINE 2 IRA AKSELRAD AND ROBERT WOOD JOHNSON, IV (PAST CHAIRMAN OF THE BOARD), HAVE A BUSINESS RELATIONSHIP. RICHARD K. DESCHERER (CO-CHAIR) AND JENNIE DESCHERER HAVE A FAMILY RELATIONSHIP. FORM 990, PART VI, SECTION B, LINE 11B AFTER PREPARATION OF FORM 990 BY LRA'S AUDITOR, LUTZ AND CARR, THE 990 IS REVIEWED BY THE LRA'S EXECUTIVE OFFICERS, THE CHIEF FINANCIAL OFFICER AND THE PRESIDENT. THE FINANCE AND AUDIT COMMITTEE OF THE BOARD THEN MEETS TO REVIEW THE 990 BEFORE FILING AND APPROVES FOR FILING WITH ANY NOTED CHANGES. A DRAFT OF THE 990 IS THEN SENT OUT TO THE FULL BOARD FOR COMMENT PRIOR TO FILING WITH THE IRS. THE FINAL FORM 990 IS PRESENTED TO THE FULL BOARD AT THE NEXT SCHEDULED MEETING. FORM 990, PART VI, SECTION B, LINE 12C THE EXECUTIVE COMMITTEE OF THE BOARD IS RESPONSIBLE FOR MONITORING CONFLICTS OF INTEREST. AN ANNUAL CONFLICT OF INTEREST DISCLOSURE FORM IS REQUIRED TO BE FILLED OUT EACH YEAR BY BOARD MEMBERS, OFFICERS AND KEY EMPLOYEES. FORM 990, PART VI, SECTION B, LINE 15 THE COMPENSATION COMMITTEE OF THE BOARD OF DIRECTORS ASSISTED THE BOARD IN FULFILLING ITS OVERSIGHT RESPONSIBILITIES RELATING TO THE COMPENSATION AND BENEFITS OF THE PRESIDENT AND OTHER EXECUTIVE OFFICERS; AND PROVIDED RECOMMENDATIONS REGARDING MANAGEMENT SUCCESSORS. ANNUALLY THE COMMITTEE REVIEWS AND RECOMMENDS TO THE BOARD THE SALARY FOR THE PRESIDENT AND OTHER OFFICERS/KEY EMPLOYEES. IN 2023, THE COMMITTEE REVIEWED AND APPROVED BASE SALARIES, 2024 COMPENSATION PLAN INCLUDING THE 2023 YEAR-END BONUS POOL FOR ALL STAFF AND THE 403B NON-ELECTIVE EMPLOYER CONTRIBUTION TO ALL ELIGIBLE STAFF. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION'S GOVERNING DOCUMENTS ARE AVAILABLE UPON REQUEST, THE CONFLICT OF INTEREST POLICY AND FINANCIAL STATEMENTS ARE ALSO AVAILABLE UPON REQUEST AND ARE ON THE FINANCIALS PAGE OF OUR WEBSITE AND ON GUIDESTAR.ORG FORM 990, PART XI, LINE 9: CANCELLED GRANTS 308,341. FORM 990, PART V, QUESTION 2A THE LRA CONTRACTS WITH TRINET, A PROFESSIONAL EMPLOYER ORGANIZATION (PEO), TO PROVIDE PAYROLL AND BENEFITS AS A CO-EMPLOYER WITH THE LRA. LRA PAYROLL AND BENEFITS ARE ADMINISTERED BY TRINET AS APPROVED BY LRA OFFICERS. LRA PAYROLL IS THEREFORE UNDER THE TRINET EIN: 13-3867443 AND W-2'S ARE PREPARED UNDER THAT EIN BY TRINET. LUPUS THERAPEUTICS LLC 270 MADISON AVENUE NEW YORK NY 10016 823984908 LRA'S CLINICAL TRIAL AFFILIATE, OVERSEEING CLINICAL RESEARCH ACTIVITY NY 2783447 624656 YES